Par to ship generic Tambocor
Executive Summary
Par's generic version of 3M's antiarrhythmic Tambocor expected to ship within 30 days, company says May 3. Par expects to have about 150 days of generic exclusivity. The company believes generic exclusivity was triggered by an appellate court decision invalidating 3M's Tambocor patents. 3M had appealed a May 2001 Minneapolis federal court verdict in favor of Barr, which was second to file an ANDA for flecainide (1"The Pink Sheet" April 8, p. 26)...
You may also be interested in...
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix
A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.